SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPenâ„¢ ...
Common side effects of Actemra include headache, high blood pressure, upper respiratory infections, and injection site reactions like itching or redness. Serious side effects may include infections ...
March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...
The FDA approval of the ACTPen was supported by data from 2 studies: an open-label, randomized, 2-period, crossover Phase 1 study (N=188), and an open-label, non-randomized, observational Phase 4 ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved ACTPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of adult ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
Actemra (tocilizumab) has been given an emergency use authorization (EUA). This EUA allows for in-hospital use of Actemra as a treatment for COVID-19 in certain cases. You should not take any ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the subcutaneous formulation of Actemra for the treatment of polyarticular juvenile ...
The FDA approval was based on a retrospective analysis of pooled outcome data from clinical studies of CAR T cell therapies for blood cancers that evaluated Actemra for the treatment of CRS. Genentech ...
ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of a global Phase III, randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results